<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><?subarticle report27443?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">AAS Open Res</journal-id><journal-id journal-id-type="iso-abbrev">AAS Open Res</journal-id><journal-id journal-id-type="pmc">AAS Open Res</journal-id><journal-title-group><journal-title>AAS Open Research</journal-title></journal-title-group><issn pub-type="epub">2515-9321</issn><publisher><publisher-name>F1000 Research Limited</publisher-name><publisher-loc>London, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12688/aasopenres.13059.1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Open Letter</subject></subj-group><subj-group><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Current and emerging diagnostic tests available for the novel COVID-19 global pandemic</article-title><fn-group content-type="pub-status"><fn><p>[version 1; peer review: 2 approved]</p></fn></fn-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mboowa</surname><given-names>Gerald</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data Curation</role><role content-type="http://credit.casrai.org/">Formal Analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project Administration</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; Original Draft Preparation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; Review &#x00026; Editing</role><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8445-9414</contrib-id><xref ref-type="corresp" rid="c1">a</xref><xref ref-type="aff" rid="a1">1</xref><xref ref-type="aff" rid="a2">2</xref></contrib><aff id="a1">
<label>1</label>The African Center of Excellence in Bioinformatics and Data-Intensive Sciences, The Infectious Disease Institute, Makerere University, Kampala, Uganda</aff><aff id="a2">
<label>2</label>Department of Immunology and Molecular Biology, College of Health Sciences, Makerere University, Kampala, Uganda</aff></contrib-group><author-notes><corresp id="c1"><label>a</label><email xlink:href="mailto:gmboowa@gmail.com">gmboowa@gmail.com</email></corresp><fn fn-type="COI-statement"><p>No competing interests were disclosed.</p></fn></author-notes><pub-date pub-type="epub"><day>24</day><month>4</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>4</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>3</volume><elocation-id>8</elocation-id><history><date date-type="accepted"><day>15</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2020 Mboowa G</copyright-statement><copyright-year>2020</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="aasopenres-3-14154.pdf"/><abstract><p>On March 11, 2020 the World Health Organization (WHO) upgraded the status of the coronavirus disease 2019 (COVID-19) outbreak from epidemic to a global pandemic. This infection is caused by a novel coronavirus, SARS-CoV-2. Several rapid diagnostic tests have been developed at an astonishing pace; however, COVID-19 requires more highly specific rapid point-of-care diagnostic tests. This review describes the currently available testing approaches, as well as the available test assays including the Xpert&#x000ae; Xpress SARS-CoV-2 test (takes
<sub>~</sub>45 min) and Abbott ID COVID-19 test (5 min) as easy to use point-of-care tests for diagnosis of novel COVID-19 that have so far received the US Food and Drug Administration emergency use authorizations clearance. This review is correct as of the date published and will be updated as more diagnostic tests come to light.</p></abstract><kwd-group kwd-group-type="author"><kwd>Coronavirus</kwd><kwd>COVID-19</kwd><kwd>diagnosis</kwd><kwd>genome sequencing</kwd><kwd>SARS-CoV-2</kwd><kwd>Point-of-Care test</kwd></kwd-group><funding-group><award-group id="fund-1"><funding-source>DELTAS Africa</funding-source><award-id>DEL-15-011toTHRiVE-2</award-id></award-group><award-group id="fund-2" xlink:href="http://dx.doi.org/10.13039/501100011858"><funding-source>African Academy of Sciences</funding-source><award-id>GrandChallengesAfrica</award-id></award-group><funding-statement>GM is supported through the DELTAS Africa Initiative [DEL-15-011 to THRiVE-2]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)&#x02019;s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa&#x02019;s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [107742/Z/15/Z] and the UK government. The views expressed in this publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government.
GM also is supported through the Grand Challenges Africa programme [GCA/AMR/rnd2/058]. Grand Challenges Africa is a programme of the African Academy of Sciences (AAS) implemented through the Alliance for Accelerating Excellence in Science in Africa (AESA) platform, an initiative of the AAS and the African Union Development Agency (AUDA-NEPAD). GC Africa is supported by the Bill &#x00026; Melinda Gates Foundation (BMGF) and The African Academy of Sciences and partners. The views expressed herein are those of the author(s) and not necessarily those of the AAS and her partners.</funding-statement><funding-statement><italic>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</italic></funding-statement></funding-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Infectious diseases are still a major threat in the world today
<sup><xref rid="ref-1" ref-type="bibr">1</xref></sup>. The diagnosis and real-time tracking of both emerging
<sup><xref rid="ref-2" ref-type="bibr">2</xref></sup> and re-emerging infectious diseases must be reliable, fast, and affordable. Healthcare systems use different approaches to make infectious diseases diagnoses, such as clinical assessment (signs and symptoms), microscopy, microbiological cultures, radiology, molecular techniques &#x02013; classical or real-time polymerase chain reaction (PCR), genome sequencing (detection presence of nucleic acid), serology (detection of the pathogens or host antibodies), artificial intelligence and machine learning
<sup><xref rid="ref-3" ref-type="bibr">3</xref></sup>. In modern medical diagnostics, whole or targeted genome sequencing or detection technologies are indispensable. In the event of novel pathogens, such as coronavirus, these technologies offer the shortest turnaround time (TAT) for results to be reported. Coupling comprehensive clinical evaluation, triaging, genomic-based diagnostics, and epidemiology to innovative digital disease detection raises the possibility of an open, global, pathogen surveillance system.</p><p>In the current case of the coronavirus global pandemic 2019, healthcare systems have the challenge of massive testing, isolating (quarantine) those suspected of being exposed to the virus, re-testing (at the end of the viral incubation period), treating and managing those who turn out to be positive, as well as real-time tracing of their contacts. The diagnosis of a novel infectious disease such as COVID-19 furthermore presents a challenge of studying and understanding its pathogenesis before developing rapid test assays to be used to subsequently diagnose cases as the disease continues to infect more people. In the development of such a test, aspects such as sensitivity, specificity, false positive and false negative rates of a diagnostic test have to be meticulously considered. As this is a great undertaking requiring high scientific expertise, laboratory and financial resources, some nations especially low-income settings have had to rely on such support from developed nations to make modifications at a country level so that they reach their healthcare needs
<sup><xref rid="ref-4" ref-type="bibr">4</xref></sup>.</p><p>The current COVID-19 outbreak has confronted scientists with an unprecedented infectious disease challenge that demands the highest level of sharing of infectious disease-related information as such infectious disease outbreaks are becoming less confined by geographical or climatic boundaries
<sup><xref rid="ref-5" ref-type="bibr">5</xref>,
<xref rid="ref-6" ref-type="bibr">6</xref></sup>. Data sharing ensures that other nations use available facts and minimize wastage of time and resources. Another lesson learnt from this pandemic is that nations should also end secrecy in public health decision-making especially amidst suspected disease outbreaks and promote global cooperation
<sup><xref rid="ref-5" ref-type="bibr">5</xref></sup>. Globally, governments should be ready to share outbreak information on acquisition, transmission, and treatment as well as make efforts to fight the spreading of &#x02018;fake news&#x02019; related to outbreaks. Nations with networks of high-containment biological laboratories must guarantee safety of all agents in their custody to prevent their potential deployment as bioweapons.</p><p>This review briefly describes the currently available testing approaches, as well as selected two easy to use point-of-care test assays, including the Xpert
<sup>&#x000ae;</sup> Xpress SARS-CoV-2 and Abbott ID COVID-19 tests, for diagnosis of novel COVID-19 infection. At the date of this publication, the US Food and Drug Administration (FDA) has granted emergency use authorizations clearance for 32 tests, as seen in
<xref rid="T1" ref-type="table">Table 1</xref>. A routinely updated list of FDA approved tests can be accessed
<ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations#coronavirus2019">here</ext-link>. </p><table-wrap id="T1" orientation="portrait" position="anchor"><label>Table 1. </label><caption><title>Coronavirus disease 2019 (COVID-19) diagnostic tests that have currently received Emergency Use Authorizations (EUA) by the US Food and Drug Administration.</title></caption><table frame="hsides" rules="groups" content-type="article-table"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Date EUA
<break/>issued</th><th align="left" valign="top" rowspan="1" colspan="1">Manufacturer</th><th align="left" valign="top" rowspan="1" colspan="1">Diagnostic name</th><th align="left" valign="top" rowspan="1" colspan="1">Principle action</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">04/08/2020</td><td align="left" valign="top" rowspan="1" colspan="1">DiaCarta, Inc</td><td align="left" valign="top" rowspan="1" colspan="1">QuantiVirus SARS-CoV-2 Test kit</td><td align="left" valign="top" rowspan="1" colspan="1">qRT-PCR for N, Orf1ab and E genes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">04/08/2020</td><td align="left" valign="top" rowspan="1" colspan="1">Becton, Dickinson &#x00026; Company</td><td align="left" valign="top" rowspan="1" colspan="1">BD SARS-CoV-2Reagents for BD
<break/>MAX System</td><td align="left" valign="top" rowspan="1" colspan="1">Multiplex qRT-PCR for N1 and N2 regions,
<break/>and the human RNase P gene</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">04/07/2020</td><td align="left" valign="top" rowspan="1" colspan="1">InBios International, Inc</td><td align="left" valign="top" rowspan="1" colspan="1">Smart Detect SARS-CoV-2 rRT-PCR
<break/>Kit</td><td align="left" valign="top" rowspan="1" colspan="1">Multiplex qRT-PCR for N, Orf1ab and E genes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">04/06/2020</td><td align="left" valign="top" rowspan="1" colspan="1">Gnomegen LLC</td><td align="left" valign="top" rowspan="1" colspan="1">Gnomegen COVID-19 RT-Digital PCR
<break/>Detection Kit</td><td align="left" valign="top" rowspan="1" colspan="1">Real-time RT-digital PCR for N1 and N2
<break/>regions, and the human RNase P gene</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">04/03/2020</td><td align="left" valign="top" rowspan="1" colspan="1">Co-Diagnostics, Inc.</td><td align="left" valign="top" rowspan="1" colspan="1">Logix Smart Coronavirus Disease
<break/>2019 (COVID-19) Kit</td><td align="left" valign="top" rowspan="1" colspan="1">rRT-PCR for
<italic>RdRp</italic> gene</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">04/03/2020</td><td align="left" valign="top" rowspan="1" colspan="1">ScienCell Research Laboratories</td><td align="left" valign="top" rowspan="1" colspan="1">ScienCell SARS-CoV-2 Coronavirus
<break/>Real-time RT-PCR (RT-qPCR) Detection Kit</td><td align="left" valign="top" rowspan="1" colspan="1">rRT-PCR for N and Human RPP30 genes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">04/03/2020</td><td align="left" valign="top" rowspan="1" colspan="1">Luminex Corporation</td><td align="left" valign="top" rowspan="1" colspan="1">ARIES SARS-CoV-2 Assay</td><td align="left" valign="top" rowspan="1" colspan="1">Multiplex qRT-PCR for ORF1ab, E gene, and N gene</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">04/02/2020</td><td align="left" valign="top" rowspan="1" colspan="1">Becton, Dickinson &#x00026; Company (BD)</td><td align="left" valign="top" rowspan="1" colspan="1">BioGX SARS-CoV-2 Reagents for BD
<break/>MAX System</td><td align="left" valign="top" rowspan="1" colspan="1">Multiplexed qRT-PCR for N1 and RNase P</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">04/01/2020</td><td align="left" valign="top" rowspan="1" colspan="1">Ipsum Diagnostics, LLC</td><td align="left" valign="top" rowspan="1" colspan="1">COV-19 IDx assay</td><td align="left" valign="top" rowspan="1" colspan="1">Multiplexed qRT-PCR for N and RNase P</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">04/01/2020</td><td align="left" valign="top" rowspan="1" colspan="1">Cellex Inc.</td><td align="left" valign="top" rowspan="1" colspan="1">qSARS-CoV-2 IgG/IgM Rapid Test</td><td align="left" valign="top" rowspan="1" colspan="1">IgM and IgG antibodies against SARSCoV-2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">03/30/2020</td><td align="left" valign="top" rowspan="1" colspan="1">QIAGEN GmbH</td><td align="left" valign="top" rowspan="1" colspan="1">QIAstat-Dx Respiratory SARS-CoV-2
<break/>Panel</td><td align="left" valign="top" rowspan="1" colspan="1">Multiplexed qRT-PCR for Orf1b poly gene
<break/>(Rdrp gene) and E gene</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">03/30/2020</td><td align="left" valign="top" rowspan="1" colspan="1">NeuMoDx Molecular, Inc.</td><td align="left" valign="top" rowspan="1" colspan="1">NeuMoDx SARS-CoV-2 Assay</td><td align="left" valign="top" rowspan="1" colspan="1">Multiplexed qRT-PCR for Nsp2 gene and N
<break/>gene</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">03/27/2020</td><td align="left" valign="top" rowspan="1" colspan="1">Luminex Molecular Diagnostics,
<break/>Inc.</td><td align="left" valign="top" rowspan="1" colspan="1">NxTAG CoV Extended Panel Assay</td><td align="left" valign="top" rowspan="1" colspan="1">Multiplex qRT-PCR for ORF1ab, and E gene</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">03/27/2020</td><td align="left" valign="top" rowspan="1" colspan="1">Abbott Diagnostics Scarborough,
<break/>Inc.</td><td align="left" valign="top" rowspan="1" colspan="1">ID NOW COVID-19</td><td align="left" valign="top" rowspan="1" colspan="1">rRT-PCR for; RdRp gene</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">03/26/2020</td><td align="left" valign="top" rowspan="1" colspan="1">BGI Genomics Co. Ltd</td><td align="left" valign="top" rowspan="1" colspan="1">Real-Time Fluorescent RT-PCR Kit for
<break/>Detecting SARS-2019-nCoV</td><td align="left" valign="top" rowspan="1" colspan="1">Multiplex qRT-PCR for N gene, E gene, and
<break/>RdRp gene</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">03/25/2020</td><td align="left" valign="top" rowspan="1" colspan="1">Avellino Lab USA, Inc.</td><td align="left" valign="top" rowspan="1" colspan="1">AvellinoCoV2 test</td><td align="left" valign="top" rowspan="1" colspan="1">rRT-PCR for N gene</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">03/24/2020</td><td align="left" valign="top" rowspan="1" colspan="1">PerkinElmer, Inc.</td><td align="left" valign="top" rowspan="1" colspan="1">PerkinElmer New Coronavirus Nucleic
<break/>Acid Detection Kit</td><td align="left" valign="top" rowspan="1" colspan="1">Multiplex qRT-PCR for ORF1ab and N genes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">03/23/2020</td><td align="left" valign="top" rowspan="1" colspan="1">Mesa Biotech Inc.</td><td align="left" valign="top" rowspan="1" colspan="1">Accula SARS-Cov-2 Test</td><td align="left" valign="top" rowspan="1" colspan="1">rRT-PCR for N gene</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">03/23/2020</td><td align="left" valign="top" rowspan="1" colspan="1">BioFire Defense, LLC</td><td align="left" valign="top" rowspan="1" colspan="1">BioFire COVID-19 Test</td><td align="left" valign="top" rowspan="1" colspan="1">Nested multiplex real-time RT-PCR for
<break/>ORF1ab, ORF8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">03/20/2020</td><td align="left" valign="top" rowspan="1" colspan="1">Cepheid</td><td align="left" valign="top" rowspan="1" colspan="1">Xpert Xpress SARS-CoV-2 test</td><td align="left" valign="top" rowspan="1" colspan="1">Multiplex qRT-PCR for E and N2 genes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">03/20/2020</td><td align="left" valign="top" rowspan="1" colspan="1">Primerdesign Ltd.</td><td align="left" valign="top" rowspan="1" colspan="1">Primerdesign Ltd COVID-19 genesig
<break/>Real-Time PCR assay</td><td align="left" valign="top" rowspan="1" colspan="1">rRT-PCR for RdRp gene</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">03/19/2020</td><td align="left" valign="top" rowspan="1" colspan="1">GenMark Diagnostics, Inc.</td><td align="left" valign="top" rowspan="1" colspan="1">ePlex SARS-CoV-2 Test</td><td align="left" valign="top" rowspan="1" colspan="1">rRT-PCR for N gene</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">03/19/2020</td><td align="left" valign="top" rowspan="1" colspan="1">DiaSorin Molecular LLC</td><td align="left" valign="top" rowspan="1" colspan="1">Simplexa COVID-19 Direct assay</td><td align="left" valign="top" rowspan="1" colspan="1">Multiplex qRT-PCR for ORF1ab and S genes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">03/18/2020</td><td align="left" valign="top" rowspan="1" colspan="1">Abbott Molecular</td><td align="left" valign="top" rowspan="1" colspan="1">Abbott RealTime SARS-CoV-2 assay</td><td align="left" valign="top" rowspan="1" colspan="1">Multiplex qRT-PCR for RdRp and N genes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">03/17/2020</td><td align="left" valign="top" rowspan="1" colspan="1">Quest Diagnostics Infectious
<break/>Disease, Inc.</td><td align="left" valign="top" rowspan="1" colspan="1">Quest SARS-CoV-2 rRT-PCR</td><td align="left" valign="top" rowspan="1" colspan="1">rRT-PCR for N gene (N1 and N3 genes)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">03/17/2020</td><td align="left" valign="top" rowspan="1" colspan="1">Quidel Corporation</td><td align="left" valign="top" rowspan="1" colspan="1">Lyra SARS-CoV-2 Assay</td><td align="left" valign="top" rowspan="1" colspan="1">rRT-PCR for ORF1ab</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">03/16/2020</td><td align="left" valign="top" rowspan="1" colspan="1">Laboratory Corporation of America
<break/>(LabCorp)</td><td align="left" valign="top" rowspan="1" colspan="1">
<underline>COVID-19 RT-PCR Test</underline>
</td><td align="left" valign="top" rowspan="1" colspan="1">rRT-PCR for N gene</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">03/16/2020</td><td align="left" valign="top" rowspan="1" colspan="1">Hologic, Inc.</td><td align="left" valign="top" rowspan="1" colspan="1">Panther Fusion SARS-CoV-2</td><td align="left" valign="top" rowspan="1" colspan="1">rRT-PCR for RdRp gene</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">03/13/2020</td><td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific, Inc.</td><td align="left" valign="top" rowspan="1" colspan="1">TaqPath COVID-19 Combo Kit</td><td align="left" valign="top" rowspan="1" colspan="1">Multiplex qRT-PCR for ORF1ab, N gene, S
<break/>gene, MS2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">03/12/2020</td><td align="left" valign="top" rowspan="1" colspan="1">Roche Molecular Systems, Inc.
<break/>(RMS)</td><td align="left" valign="top" rowspan="1" colspan="1">cobas SARS-CoV-2</td><td align="left" valign="top" rowspan="1" colspan="1">Multiplex qRT-PCR for ORF-1a and E-gene</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">02/29/2020</td><td align="left" valign="top" rowspan="1" colspan="1">Wadsworth Center, New York State
<break/>Department of Public Health's
<break/>(CDC)</td><td align="left" valign="top" rowspan="1" colspan="1">New York SARS-CoV-2 Real-time
<break/>Reverse Transcriptase (RT)-PCR
<break/>Diagnostic Panel</td><td align="left" valign="top" rowspan="1" colspan="1">rRT-PCR for N gene</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">02/04/2020</td><td align="left" valign="top" rowspan="1" colspan="1">Centers for Disease Control and
<break/>Prevention's (CDC)</td><td align="left" valign="top" rowspan="1" colspan="1">CDC 2019-nCoV Real-Time RT-PCR
<break/>Diagnostic Panel (CDC)</td><td align="left" valign="top" rowspan="1" colspan="1">Multiplex qRT-PCR for N1, N2, and RP genes
<break/>of the virus</td></tr></tbody></table></table-wrap></sec><sec><title>Molecular assays to diagnose COVID-19</title><p>The manifestation of the COVID-19 infection is highly nonspecific and presents respiratory symptoms, fever, cough, dyspnoea, and viral pneumonia
<sup><xref rid="ref-7" ref-type="bibr">7</xref></sup>. Thus, diagnostic tests specific to this infection are urgently required to confirm suspected cases, screen patients, and conduct virus surveillance. In this scenario, a rapid, robust, and cost-efficient device that can be used anywhere and which does not necessarily require a trained technician to operate
<sup><xref rid="ref-8" ref-type="bibr">8</xref></sup> (i.e. at point-of-care) is crucial and urgently needed for the detection of COVID-19
<sup><xref rid="ref-9" ref-type="bibr">9</xref></sup>. Several assays that detect SARS-CoV-2
<ext-link ext-link-type="uri" xlink:href="https://www.finddx.org/covid-19/pipeline">have been developed so far</ext-link>, including Rapid IgM-IgG Combined Antibody Test For Coronavirus (RayBiotech Life), 2019-nCoV IgG/IgM Antibody Detection Kit (MyBioSource, Inc.), qSARS-CoV-2 IgG/IgM Rapid Test (Cellex, Inc.), ARIES SARS-CoV-2 Assay (Luminex Corporation), SGTi-flex COVID-19 IgM/IgG (Sugentech, Inc), while still under development is the ultrasensitive, rapid, portable coronavirus SARS-CoV-2 nucleic acid sequence detection system that uses nanobiosensor-based aptamer technology
<sup><xref rid="ref-10" ref-type="bibr">10</xref></sup> are currently under development. These are both
<italic>in-house</italic> and
<ext-link ext-link-type="uri" xlink:href="https://www.bioworld.com/COVID19diagnostics">commercially available</ext-link>. Some assays detect only the novel form of virus and some may also detect other viral strains (e.g. SARS-CoV) that are genetically similar to SARS-CoV-2
<sup><xref rid="ref-11" ref-type="bibr">11</xref></sup>. More about status of evaluation of SARS-COV-2 molecular diagnostics tests can be found
<ext-link ext-link-type="uri" xlink:href="https://www.finddx.org/covid-19/sarscov2-eval-molecular/">here</ext-link> and
<ext-link ext-link-type="uri" xlink:href="https://www.360dx.com/coronavirus-test-tracker-launched-covid-19-tests">here</ext-link>. This includes the viral molecular target utilised in the test, country of manufacturer and its regulatory status.</p></sec><sec><title>Virological culture to diagnose COVID-19</title><p>Emerging and re-emerging pathogens are global challenges for public health
<sup><xref rid="ref-12" ref-type="bibr">12</xref>,
<xref rid="ref-13" ref-type="bibr">13</xref></sup>. Laboratory biosafety requirements related to COVID-19 virus include the availability of biosafety requirements for viral cultures and further manipulations. The World Health Organisation (WHO) recommends that all procedures must be performed based on risk assessment and only by highly trained personnel with demonstrated capability in strict observance to all relevant protocols at all times
<sup><xref rid="ref-14" ref-type="bibr">14</xref></sup>. Non-propagative diagnostic laboratory work, such as viral genome sequencing and nucleic acid amplification tests, must be conducted at containment facilities and procedures equivalent to biosafety level 2 (BSL-2) while propagative work that involves coronavirus culture, isolation, animal inoculation or neutralization assays must be done at a high-biocontainment laboratory with inward directional airflow (minimum BSL-3)
<sup><xref rid="ref-14" ref-type="bibr">14</xref></sup>. Viral cultures are not recommended for routine diagnosis and must be carried in a minimum of BSL-3 facility or BSL-4
<sup><xref rid="ref-14" ref-type="bibr">14</xref></sup>. However, SARS-COV-2 virus isolation in cell cultures is critical to obtain isolates for characterization and to support the development of vaccines, therapeutic agents
<sup><xref rid="ref-15" ref-type="bibr">15</xref></sup> and new or better diagnostic tests.</p><p>SARS-CoV-2 is isolated and propagated in primary monkey cells and cell lines such as the kidney Vero-E6, LLC-MK2, Human hepatoma cell line Huh7, human airway epithelial cells, and Vero-E6/TMPRSS2 (Transmembrane Serine Protease 2)
<sup><xref rid="ref-16" ref-type="bibr">16</xref></sup>. Not all countries or jurisdictions have the facilities to perform virological culture tests for COVID-19. This is due to several reasons such as the required level of technical expertise required for the tests and biosafety requirements. Therefore, in such cases, these regions, e.g. American Samoa, have had to ship clinical samples from suspected individuals to either the US CDC laboratory in Atlanta Georgia
<sup><xref rid="ref-17" ref-type="bibr">17</xref></sup> or WHO reference testing laboratories in France, United Kingdom, China, Japan, Singapore, Australia, Thailand, India, USA, South Africa, Senegal, Russian Federation, Germany, and The Netherlands
<sup><xref rid="ref-18" ref-type="bibr">18</xref></sup>. This increases the TAT for the diagnosis even when they are shipped as expedited consignments. </p><p>In addition to virological culture, serological tests are currently under development and these could enable diagnosis of COVID-19 especially in patients for whom acute and convalescent paired samples are available. These are drawn approximately 2 weeks apart to monitor any significant changes in antibody titers of the patients. However, development of these types of tests is currently challenging due to a lack of knowledge about the antibody response elicited from the SARS-CoV-2 infection in humans, including the question concerning the antigenic differences between SARS-CoV-2 and SARS-CoV
<sup><xref rid="ref-19" ref-type="bibr">19</xref></sup>. In addition, these serological tests may face a challenge of cross-reactivity with other coronaviruses
<sup><xref rid="ref-18" ref-type="bibr">18</xref></sup>. However, the FDA has offered emergency use authorization of the first antibody-based test for COVID-19 that detects antibodies in the one&#x02019;s blood, rather than for the virus in the nose or throat samples. This test is only done at certified laboratories and even though it takes 15 to 20 minutes to get a result after sample collection, it is not a bedside test
<sup><xref rid="ref-20" ref-type="bibr">20</xref></sup>. </p></sec><sec><title>Point-of-care tests to diagnose COVID-19</title><p>Point-of-care testing means that results are delivered to patients in the patient care setting, such as hospitals, urgent care centers and medical emergency rooms, instead of samples being sent to a testing laboratory. Real-time PCR, also known as quantitative PCR, is commonly used in molecular point-of-care testing. It can amplify more than one genomic target and in the case of COVID-19 and these can be
<italic>ORF1ab</italic> of coronaviruses occupy about two thirds of their genomes. It encodes the replicase polyprotein and is translated from ORF1a and ORF1b,
<italic>E</italic>-gene (envelope protein) and
<italic>N</italic>-gene (the nucleocapsid protein)
<sup><xref rid="ref-21" ref-type="bibr">21</xref></sup> and RNA-dependent RNA polymerase (RdRp) that is an essential viral enzyme, which replicates positive-strand RNA viral genome. For more specificity, some molecular diagnostic assays amplify more than one molecular target in the virus to minimize chances of all three targets mutating and hence being missed by the diagnostic test
<sup><xref rid="ref-21" ref-type="bibr">21</xref></sup>. During the development of disease testing assays, US manufacturers can apply for emergency clinical use authorization from FDA, and in the European Union manufacturers can obtain "Conformit&#x000e9; Europ&#x000e9;ene" which literally means "European Conformity", marking them for
<italic>in vitro</italic> diagnostic use.</p><p>On March 21, 2020, the US FDA granted emergency use authorization to a rapid, point-of-care diagnostic test designed to detect COVID-19 infection
<sup><xref rid="ref-22" ref-type="bibr">22</xref></sup>. This test, Xpert
<sup>&#x000ae;</sup> Xpress SARS-CoV-2, was developed by Cepheid (Sunnyvale, California, USA) to detect SARS-CoV-2 in approximately 45 minutes, following clinical specimen collection from a nasopharyngeal swab, nasal wash or aspirate. The Xpert
<sup>&#x000ae;</sup> Xpress SARS-CoV-2 test cartridge is designed to detect nucleic acid from SARS-CoV-2 via real-time PCR
<sup><xref rid="ref-23" ref-type="bibr">23</xref></sup>. Xpert
<sup>&#x000ae;</sup> Xpress SARS-CoV-2 detects two targets,
<italic>E</italic> and
<italic>N</italic>2 genes
<sup><xref rid="ref-24" ref-type="bibr">24</xref></sup>. Furthermore, GeneXpert infinity automated systems do not require users to have special training to perform testing. The
<ext-link ext-link-type="uri" xlink:href="https://p.widencdn.net/psq91e/Cepheid-GeneXpert-System-Menu-Flyer-CE-IVD-0293-English">Xpert</ext-link> is capable of running 24/7, with many systems already doing so today for other infectious diseases, such as tuberculosis (Xpert
<sup>&#x000ae;</sup> MTB/RIF)
<sup><xref rid="ref-25" ref-type="bibr">25</xref></sup>,
<italic>Chlamydia trachomatis</italic> and
<italic>Neisseria gonorrhoeae</italic> (Xpert
<sup>&#x000ae;</sup> CT/NG)
<sup><xref rid="ref-26" ref-type="bibr">26</xref></sup>, methicillin-resistant
<italic>Staphylococcus aureus</italic> (Xpert
<sup>&#x000ae;</sup> MRSA)
<sup><xref rid="ref-27" ref-type="bibr">27</xref></sup>, Group A Streptococcus (Xpert
<sup>&#x000ae;</sup> Xpress Strep A)
<sup><xref rid="ref-28" ref-type="bibr">28</xref></sup> and Ebola (Xpert
<sup>&#x000ae;</sup> Ebola)
<sup><xref rid="ref-29" ref-type="bibr">29</xref></sup>.</p><p>A second FDA approved test is Abbott ID NOW&#x02122; COVID-19, which runs on the Abbott ID NOW&#x02122; platform &#x02013; a lightweight box that can sit in a variety of locations. Positive results can be detected in as little as 5 minutes while negative results take 13 minutes. This test applies molecular technology targeting the COVID-19
<italic>RdRp</italic> gene
<sup><xref rid="ref-30" ref-type="bibr">30</xref></sup>. In addition, the above two COVID-19 molecular diagnostic tests are designed for near patient testing in a variety of healthcare environments using a range of sample types such as throat, nasal, nasopharyngeal and oropharyngeal swabs and this facilitates effective patient management.</p><p>As the number of confirmed cases of COVID-19 rises rapidly throughout the world, more and more nations continue to require reliable testing. A rapid, inexpensive, and easy-to-use point-of-care diagnostic device integrated with a smartphone could reduce transportation needs, lower the risk of spreading infection, alleviate the strain on the healthcare system, and mitigate the cost of testing for both individuals and governments
<sup><xref rid="ref-31" ref-type="bibr">31</xref></sup>. Unfortunately, scaling up production of available COVID-19 diagnostics, as well as personal protective equipment, remain an ongoing challenge in the fight against this disease. A list of other diagnostics under development and testing are listed here
<sup><xref rid="ref-32" ref-type="bibr">32</xref></sup>. The WHO prequalification team activated the emergency use listing (EUL) for candidates in vitro diagnostics to detect SARS-CoV-2. There is currently a total of 30 different diagnostic tests at the time of this publication
<sup><xref rid="ref-33" ref-type="bibr">33</xref></sup>. Since SARS-CoV-2 diagnostics development and approval are rapidly changing, this information is updated weekly at the
<ext-link ext-link-type="uri" xlink:href="https://www.who.int/diagnostics_laboratory/EUL/en/">WHO portal</ext-link>. As governments around the world are being encouraged by WHO to rapidly test a very large percentage of their populations to fight coronavirus
<sup><xref rid="ref-34" ref-type="bibr">34</xref></sup>, these tests will be critical in meeting this demand.</p></sec><sec><title>Whole-genome sequencing for COVID-19</title><p>Following the emergence of SARS-CoV-2, genomic analyses continue to play a key role in the public health response by informing the design of appropriate molecular diagnostics and corroborating epidemiological efforts to trace contacts
<sup><xref rid="ref-35" ref-type="bibr">35</xref></sup>. In order to better understand the spread of this pandemic and design better interventions, whole genome sequencing of the virus from a range of clinical presentations of the disease in different parts of the world must occur (
<xref ref-type="fig" rid="f1">Figure 1</xref>). It has been suggested from rapid data sharing using publicly available sequence data platforms that this pandemic was a point-source outbreak
<sup><xref rid="ref-35" ref-type="bibr">35</xref>,
<xref rid="ref-36" ref-type="bibr">36</xref></sup>. Therefore, researchers need more data from the whole genomes of SARS-CoV-2 including viral transcriptome
<sup><xref rid="ref-37" ref-type="bibr">37</xref></sup>. All these have the potential to reveal further insights into the biology of this emergent pathogen
<sup><xref rid="ref-35" ref-type="bibr">35</xref></sup>. Nanopore MinION sequencing technology has been used to sequence SARS-CoV-2 genomes
<sup><xref rid="ref-38" ref-type="bibr">38</xref>,
<xref rid="ref-39" ref-type="bibr">39</xref></sup>. Many of these genomes have been successfully uploaded to Global Initiative on Sharing All Influenza Data -
<ext-link ext-link-type="uri" xlink:href="https://www.gisaid.org/">GISAID</ext-link> by the WHO reference laboratories globally and
<ext-link ext-link-type="uri" xlink:href="https://nextstrain.org/ncov">Nextstrain</ext-link>. Other public repositories that have a number of these sequences are GenBank and the Sequence Read Archive of the US National Center for Biotechnology.</p><fig fig-type="figure" id="f1" orientation="portrait" position="anchor"><label>Figure 1. </label><caption><title>Utility of SARS-CoV-2 whole-genome sequencing.</title></caption><graphic xlink:href="aasopenres-3-14154-g0000"/></fig></sec><sec><title>The future of COVID-19 rapid point-of-care tests</title><p>Currently with more than 2.6 million infected individuals in 185 sovereign states and 183,000 deaths globally
<sup><xref rid="ref-40" ref-type="bibr">40</xref></sup> at the time of writing, the COVID-19 pandemic may see deployment of COVID-19 rapid non-invasive point-of-care tests at civil airports and national borders to screen individuals and avoid imported cases of the infection. This would be similar to mitigation of aircraft hijackings and in-flight sabotage using mandatory civil aviation security procedures, including strict security screening for passengers and baggage at all commercial airports
<sup><xref rid="ref-41" ref-type="bibr">41</xref></sup>. Currently, screening for COVID-19 is performed by checking for high fever in individuals coming through airports and border controls using thermal screening guns. A nanosensor diagnostic platform is in development to test for this virus, which will replace thermal screening guns and be more specific. This technology, which will be in the form of a hand-held device, promises to give results specific for this virus within one minute, by detecting the nucleocapsid protein specific for this virus using nanosensor and aptamer technology
<sup><xref rid="ref-21" ref-type="bibr">21</xref></sup>.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>To minimise the current COVID-19 pandemic related pressure on health systems globally, especially arising from ramping up testing capacity quickly, readily accessible, cheap, easy to use and interpret point-of-care diagnostic tests with high sensitivity must be developed, produced and distributed widely.</p></sec><sec sec-type="data-availability"><title>Data availability</title><p>No data is associated with this article.</p></sec></body><back><ref-list><ref id="ref-1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mongan</surname><given-names>AE</given-names></name><name><surname>Tuda</surname><given-names>JSB</given-names></name><name><surname>Runtuwene</surname><given-names>LR</given-names></name></person-group>:
<article-title>Portable sequencer in the fight against infectious disease.</article-title>
<source><italic toggle="yes">J Hum Genet.</italic></source>
<year>2020</year>;<volume>65</volume>(<issue>1</issue>):<fpage>35</fpage>&#x02013;<lpage>40</lpage>.
<pub-id pub-id-type="doi">10.1038/s10038-019-0675-4</pub-id>
<!--<pub-id pub-id-type="pmcid">6892364</pub-id>-->
<?supplied-pmid 31582773?><pub-id pub-id-type="pmid">31582773</pub-id></mixed-citation></ref><ref id="ref-2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gardy</surname><given-names>JL</given-names></name><name><surname>Loman</surname><given-names>NJ</given-names></name></person-group>:
<article-title>Towards a genomics-informed, real-time, global pathogen surveillance system.</article-title>
<source><italic toggle="yes">Nat Rev Genet.</italic></source>
<year>2018</year>;<volume>19</volume>(<issue>1</issue>):<fpage>9</fpage>&#x02013;<lpage>20</lpage>.
<pub-id pub-id-type="doi">10.1038/nrg.2017.88</pub-id>
<!--<pub-id pub-id-type="pmcid">7097748</pub-id>-->
<?supplied-pmid 29129921?><pub-id pub-id-type="pmid">29129921</pub-id></mixed-citation></ref><ref id="ref-3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jiang</surname><given-names>F</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Zhi</surname><given-names>H</given-names></name><etal/></person-group>:
<article-title>Artificial intelligence in healthcare: past, present and future.</article-title>
<source><italic toggle="yes">Stroke Vasc Neurol.</italic></source>
<year>2017</year>;<volume>2</volume>(<issue>4</issue>):<fpage>230</fpage>&#x02013;<lpage>243</lpage>.
<pub-id pub-id-type="doi">10.1136/svn-2017-000101</pub-id>
<!--<pub-id pub-id-type="pmcid">5829945</pub-id>-->
<?supplied-pmid 29507784?><pub-id pub-id-type="pmid">29507784</pub-id></mixed-citation></ref><ref id="ref-4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ayebare</surname><given-names>RR</given-names></name><name><surname>Flick</surname><given-names>R</given-names></name><name><surname>Okware</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>Adoption of COVID-19 triage strategies for low-income settings.</article-title>
<source><italic toggle="yes">Lancet Respir Med.</italic></source>
<year>2020</year>;<volume>8</volume>(<issue>4</issue>):<fpage>e22</fpage>.
<pub-id pub-id-type="doi">10.1016/S2213-2600(20)30114-4</pub-id>
<!--<pub-id pub-id-type="pmcid">7103952</pub-id>-->
<?supplied-pmid 32171063?><pub-id pub-id-type="pmid">32171063</pub-id></mixed-citation></ref><ref id="ref-5"><label>5</label><mixed-citation publication-type="journal">
<article-title>Coronavirus: three things all governments and their science advisers must do now.</article-title>
<source><italic toggle="yes">Nature.</italic></source>
<year>2020</year>;<volume>579</volume>(<issue>7799</issue>):<fpage>319</fpage>&#x02013;<lpage>320</lpage>.
<pub-id pub-id-type="doi">10.1038/d41586-020-00772-4</pub-id>
<?supplied-pmid 32184490?><pub-id pub-id-type="pmid">32184490</pub-id></mixed-citation></ref><ref id="ref-6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peters</surname><given-names>A</given-names></name></person-group>:
<article-title>The global proliferation of high-containment biological laboratories: understanding the phenomenon and its implications.</article-title>
<source><italic toggle="yes">Rev Sci Tech.</italic></source>
<year>2018</year>;<volume>37</volume>(<issue>3</issue>):<fpage>857</fpage>&#x02013;<lpage>883</lpage>.
<pub-id pub-id-type="doi">10.20506/37.3.2892</pub-id>
<?supplied-pmid 30964462?><pub-id pub-id-type="pmid">30964462</pub-id></mixed-citation></ref><ref id="ref-7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group>:
<article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.</article-title>
<source><italic toggle="yes">Lancet.</italic></source>
<year>2020</year>;<volume>395</volume>(<issue>10223</issue>):<fpage>497</fpage>&#x02013;<lpage>506</lpage>.
<pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id>
<?supplied-pmid 31986264?><pub-id pub-id-type="pmid">31986264</pub-id></mixed-citation></ref><ref id="ref-8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Zo&#x000eb;ga Andreasen</surname><given-names>S</given-names></name><name><surname>Wolff</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>From Lab on a Chip to Point of Care Devices: The Role of Open Source Microcontrollers.</article-title>
<source><italic toggle="yes">Micromachines (Basel).</italic></source>
<year>2018</year>;<volume>9</volume>(<issue>8</issue>): pii: E403.
<pub-id pub-id-type="doi">10.3390/mi9080403</pub-id>
<!--<pub-id pub-id-type="pmcid">6187319</pub-id>-->
<?supplied-pmid 30424336?><pub-id pub-id-type="pmid">30424336</pub-id></mixed-citation></ref><ref id="ref-9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Duong Bang</surname><given-names>D</given-names></name><name><surname>Wolff</surname><given-names>A</given-names></name></person-group>:
<article-title>2019 Novel Coronavirus Disease (COVID-19): Paving the Road for Rapid Detection and Point-of-Care Diagnostics.</article-title>
<source><italic toggle="yes">Micromachines (Basel).</italic></source>
<year>2020</year>;<volume>11</volume>(<issue>3</issue>): pii: E306.
<pub-id pub-id-type="doi">10.3390/mi11030306</pub-id>
<!--<pub-id pub-id-type="pmcid">7142866</pub-id>-->
<?supplied-pmid 32183357?><pub-id pub-id-type="pmid">32183357</pub-id></mixed-citation></ref><ref id="ref-10"><label>10</label><mixed-citation publication-type="journal">
<collab>rapid microbiology</collab>:
<article-title>Pinpoint&#x02019;s Low-Cost Handheld Covid-19 Aptamer-based Diagnostic Device in Development</article-title>. Accessed April 8, 2020.
<ext-link ext-link-type="uri" xlink:href="https://www.rapidmicrobiology.com/news/pinpoint39s-low-cost-handheld-covid-19-aptamer-based-diagnostic-device-in-development">Reference Source</ext-link>
</mixed-citation></ref><ref id="ref-11"><label>11</label><mixed-citation publication-type="journal">
<article-title>National laboratories</article-title>. Accessed March 22, 2020.
<ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance">Reference Source</ext-link>
</mixed-citation></ref><ref id="ref-12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group>:
<article-title>A Novel Coronavirus from Patients with Pneumonia in China, 2019.</article-title>
<source><italic toggle="yes">N Engl J Med.</italic></source>
<year>2020</year>;<volume>382</volume>(<issue>8</issue>):<fpage>727</fpage>&#x02013;<lpage>733</lpage>.
<pub-id pub-id-type="doi">10.1056/NEJMoa2001017</pub-id>
<!--<pub-id pub-id-type="pmcid">7092803</pub-id>-->
<?supplied-pmid 31978945?><pub-id pub-id-type="pmid">31978945</pub-id></mixed-citation></ref><ref id="ref-13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gao</surname><given-names>GF</given-names></name></person-group>:
<article-title>From &#x0201c;A&#x0201d;IV to &#x0201c;Z&#x0201d;IKV: Attacks from Emerging and Re-emerging Pathogens.</article-title>
<source><italic toggle="yes">Cell.</italic></source>
<year>2018</year>;<volume>172</volume>(<issue>6</issue>):<fpage>1157</fpage>&#x02013;<lpage>1159</lpage>.
<pub-id pub-id-type="doi">10.1016/j.cell.2018.02.025</pub-id>
<!--<pub-id pub-id-type="pmcid">7126677</pub-id>-->
<?supplied-pmid 29522735?><pub-id pub-id-type="pmid">29522735</pub-id></mixed-citation></ref><ref id="ref-14"><label>14</label><mixed-citation publication-type="journal">
<collab>World Health Organization</collab>:
<article-title>Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, 2 March 2020</article-title>. World Health Organization;<year>2020</year>
<ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/handle/10665/331329">Reference Source</ext-link>
</mixed-citation></ref><ref id="ref-15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Loeffelholz</surname><given-names>MJ</given-names></name><name><surname>Tang</surname><given-names>YW</given-names></name></person-group>:
<article-title>Laboratory diagnosis of emerging human coronavirus infections - the state of the art.</article-title>
<source><italic toggle="yes">Emerg Microbes Infect.</italic></source>
<year>2020</year>;<volume>9</volume>(<issue>1</issue>):<fpage>747</fpage>&#x02013;<lpage>756</lpage>.
<pub-id pub-id-type="doi">10.1080/22221751.2020.1745095</pub-id>
<?supplied-pmid 32196430?><pub-id pub-id-type="pmid">32196430</pub-id></mixed-citation></ref><ref id="ref-16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matsuyama</surname><given-names>S</given-names></name><name><surname>Nao</surname><given-names>N</given-names></name><name><surname>Shirato</surname><given-names>K</given-names></name><etal/></person-group>:
<article-title>Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells.</article-title>
<source><italic toggle="yes">Proc Natl Acad Sci.</italic></source>
<year>2020</year>;<volume>117</volume>(<issue>13</issue>):<fpage>7001</fpage>&#x02013;<lpage>7003</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.2002589117</pub-id>
<!--<pub-id pub-id-type="pmcid">7132130</pub-id>-->
<?supplied-pmid 32165541?><pub-id pub-id-type="pmid">32165541</pub-id></mixed-citation></ref><ref id="ref-17"><label>17</label><mixed-citation publication-type="journal">
<article-title>American Samoa&#x02019;s coronavirus conundrum: No way to test</article-title>. Accessed April 8, 2020.
<ext-link ext-link-type="uri" xlink:href="https://www.nbcnews.com/health/health-care/american-samoa-s-coronavirus-conundrum-no-way-test-n1167776">Reference Source</ext-link>
</mixed-citation></ref><ref id="ref-18"><label>18</label><mixed-citation publication-type="journal">
<article-title>who-reference-laboratories-providing-confirmatory-testing-for-covid-19.pdf</article-title>. Accessed March 22, 2020.
<ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/who-reference-laboratories-providing-confirmatory-testing-for-covid-19.pdf?sfvrsn=a03a01e6_2">Reference Source</ext-link>
</mixed-citation></ref><ref id="ref-19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lv</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>NC</given-names></name><name><surname>Tsang</surname><given-names>OTY</given-names></name><etal/></person-group>:
<article-title>Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections.</article-title>
<source><italic toggle="yes">bioRxiv.</italic></source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1101/2020.03.15.993097</pub-id>
</mixed-citation></ref><ref id="ref-20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wetsman</surname><given-names>N</given-names></name></person-group>:
<article-title>FDA authorizes first antibody-based test for COVID-19.</article-title>
<source><italic toggle="yes">The Verge.</italic></source>Accessed April 8, 2020.
<ext-link ext-link-type="uri" xlink:href="https://www.theverge.com/2020/4/2/21204478/fda-authorization-coronavirus-antibody-test-diagnostic-covid-19">Reference Source</ext-link>
</mixed-citation></ref><ref id="ref-21"><label>21</label><mixed-citation publication-type="journal">
<collab>rapidmicrobiology</collab>:
<article-title>Coronavirus (SARS-CoV-2): Test Kits to Detect the Causative Agent of COVID-19</article-title>. Accessed April 2, 2020.
<ext-link ext-link-type="uri" xlink:href="https://www.rapidmicrobiology.com/test-method/testing-for-the-wuhan-coronavirus-a-k-a-covid-19-sars-cov-2-and-2019-ncov">Reference Source</ext-link>
</mixed-citation></ref><ref id="ref-22"><label>22</label><mixed-citation publication-type="journal">
<article-title>Point-of-Care COVID-19 Test Gets FDA Authorization.</article-title>
<source><italic toggle="yes">HCPLive.</italic></source>Accessed March 22, 2020.
<ext-link ext-link-type="uri" xlink:href="https://www.mdmag.com/medical-news/pointofcare-covid19-test-gets-fda-authorization">Reference Source</ext-link>
</mixed-citation></ref><ref id="ref-23"><label>23</label><mixed-citation publication-type="journal">download.pdf.
<ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/media/136314/download">https://www.fda.gov/media/136314/download</ext-link>. Accessed March 22, 2020.</mixed-citation></ref><ref id="ref-24"><label>24</label><mixed-citation publication-type="journal">download.pdf.
<ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/media/136315/download">https://www.fda.gov/media/136315/download</ext-link>. Accessed April 9, 2020.</mixed-citation></ref><ref id="ref-25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Steingart</surname><given-names>KR</given-names></name><name><surname>Sohn</surname><given-names>H</given-names></name><name><surname>Schiller</surname><given-names>I</given-names></name><etal/></person-group>:
<article-title>Xpert
<sup>&#x000ae;</sup> MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.</article-title>
<source><italic toggle="yes">Cochrane Database Syst Rev.</italic></source>
<year>2013</year>; (<issue>1</issue>): CD009593.
<pub-id pub-id-type="doi">10.1002/14651858.CD009593.pub2</pub-id>
<!--<pub-id pub-id-type="pmcid">4470352</pub-id>-->
<?supplied-pmid 23440842?><pub-id pub-id-type="pmid">23440842</pub-id></mixed-citation></ref><ref id="ref-26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gaydos</surname><given-names>CA</given-names></name><name><surname>Van Der Pol</surname><given-names>B</given-names></name><name><surname>Jett-Goheen</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Performance of the Cepheid CT/NG Xpert Rapid PCR Test for Detection of
<italic>Chlamydia trachomatis</italic> and
<italic>Neisseria gonorrhoeae</italic>.</article-title>
<source><italic toggle="yes">J Clin Microbiol.</italic></source>
<year>2013</year>;<volume>51</volume>(<issue>6</issue>):<fpage>1666</fpage>&#x02013;<lpage>1672</lpage>.
<pub-id pub-id-type="doi">10.1128/JCM.03461-12</pub-id>
<!--<pub-id pub-id-type="pmcid">3716060</pub-id>-->
<?supplied-pmid 23467600?><pub-id pub-id-type="pmid">23467600</pub-id></mixed-citation></ref><ref id="ref-27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spencer</surname><given-names>DH</given-names></name><name><surname>Sellenriek</surname><given-names>P</given-names></name><name><surname>Burnham</surname><given-names>CAD</given-names></name></person-group>:
<article-title>Validation and implementation of the GeneXpert MRSA/SA blood culture assay in a pediatric setting.</article-title>
<source><italic toggle="yes">Am J Clin Pathol.</italic></source>
<year>2011</year>;<volume>136</volume>(<issue>5</issue>):<fpage>690</fpage>&#x02013;<lpage>694</lpage>.
<pub-id pub-id-type="doi">10.1309/AJCP07UGYOKBVVNC</pub-id>
<?supplied-pmid 22031306?><pub-id pub-id-type="pmid">22031306</pub-id></mixed-citation></ref><ref id="ref-28"><label>28</label><mixed-citation publication-type="journal">
<article-title>Xpert-Xpress-Strep-A-ENGLISH-Package-Insert-301-6574-Rev-C.pdf</article-title>. Accessed April 8, 2020.
<ext-link ext-link-type="uri" xlink:href="https://www.cepheid.com/Package%20Insert%20Files/Xpert-Xpress-Strep-A-ENGLISH-Package-Insert-301-6574-Rev-C.pdf">Reference Source</ext-link>
</mixed-citation></ref><ref id="ref-29"><label>29</label><mixed-citation publication-type="journal">download.pdf.
<ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/media/91944/download">https://www.fda.gov/media/91944/download</ext-link>. Accessed April 8, 2020.</mixed-citation></ref><ref id="ref-30"><label>30</label><mixed-citation publication-type="journal">
<article-title>ID NOW
<sup>TM</sup> COVID-19. Alere is now Abbott</article-title>. Accessed April 2, 2020.
<ext-link ext-link-type="uri" xlink:href="https://www.alere.com/en/home/product-details/id-now-covid-19.html">Reference Source</ext-link>
</mixed-citation></ref><ref id="ref-31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>YC</given-names></name><name><surname>Shen</surname><given-names>CF</given-names></name><etal/></person-group>:
<article-title>Point-of-Care RNA-Based Diagnostic Device for COVID-19.</article-title>
<source><italic toggle="yes">Diagnostics (Basel).</italic></source>
<year>2020</year>;<volume>10</volume>(<issue>3</issue>): pii: E165.
<pub-id pub-id-type="doi">10.3390/diagnostics10030165</pub-id>
<?supplied-pmid 32197339?><pub-id pub-id-type="pmid">32197339</pub-id></mixed-citation></ref><ref id="ref-32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sheridan</surname><given-names>C</given-names></name></person-group>:
<article-title>Fast, portable tests come online to curb coronavirus pandemic.</article-title>
<source><italic toggle="yes">Nat Biotechnol.</italic></source>
<year>2020</year>.
<pub-id pub-id-type="doi">10.1038/d41587-020-00010-2</pub-id>
<?supplied-pmid 32203294?><pub-id pub-id-type="pmid">32203294</pub-id></mixed-citation></ref><ref id="ref-33"><label>33</label><element-citation publication-type="journal">
<ext-link ext-link-type="uri" xlink:href="https://www.who.int/diagnostics_laboratory/200407_eul_covid19_ivd_update.pdf?ua=1">https://www.who.int/diagnostics_laboratory/200407_eul_covid19_ivd_update.pdf?ua=1</ext-link>
</element-citation></ref><ref id="ref-34"><label>34</label><mixed-citation publication-type="journal">
<collab>Governments Must Ramp Up COVID-19 Testing, Says WHO</collab>:
<article-title>The Scientist Magazine&#x000ae;</article-title>. Accessed April 9, 2020.
<ext-link ext-link-type="uri" xlink:href="https://www.the-scientist.com/news-opinion/governments-must-ramp-up-covid-19-testing-says-who-67287">Reference Source</ext-link>
</mixed-citation></ref><ref id="ref-35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taiaroa</surname><given-names>G</given-names></name><name><surname>Rawlinson</surname><given-names>D</given-names></name><name><surname>Featherstone</surname><given-names>L</given-names></name><etal/></person-group>:
<article-title>Direct RNA sequencing and early evolution of SARS-CoV-2.</article-title>
<source><italic toggle="yes">bioRxiv.</italic></source>
<year>2020</year>; 2020.03.05.976167.
<pub-id pub-id-type="doi">10.1101/2020.03.05.976167</pub-id>
</mixed-citation></ref><ref id="ref-36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hadfield</surname><given-names>J</given-names></name><name><surname>Megill</surname><given-names>C</given-names></name><name><surname>Bell</surname><given-names>SM</given-names></name><etal/></person-group>:
<article-title>Nextstrain: real-time tracking of pathogen evolution.</article-title>
<source><italic toggle="yes">Bioinformatics.</italic></source>
<year>2018</year>;<volume>34</volume>(<issue>23</issue>):<fpage>4121</fpage>&#x02013;<lpage>4123</lpage>.
<pub-id pub-id-type="doi">10.1093/bioinformatics/bty407</pub-id>
<!--<pub-id pub-id-type="pmcid">6247931</pub-id>-->
<?supplied-pmid 29790939?><pub-id pub-id-type="pmid">29790939</pub-id></mixed-citation></ref><ref id="ref-37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Yang</surname><given-names>JS</given-names></name><etal/></person-group>:
<article-title>The architecture of SARS-CoV-2 transcriptome.</article-title>
<source><italic toggle="yes">bioRxiv.</italic></source>
<year>2020</year>; 2020.03.12.988865.
<pub-id pub-id-type="doi">10.1101/2020.03.12.988865</pub-id>
</mixed-citation></ref><ref id="ref-38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>XL</given-names></name><name><surname>Wang</surname><given-names>XG</given-names></name><etal/></person-group>:
<article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin.</article-title>
<source><italic toggle="yes">Nature.</italic></source>
<year>2020</year>;<volume>579</volume>(<issue>7798</issue>):<fpage>270</fpage>&#x02013;<lpage>273</lpage>.
<pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id>
<!--<pub-id pub-id-type="pmcid">7095418</pub-id>-->
<?supplied-pmid 32015507?><pub-id pub-id-type="pmid">32015507</pub-id></mixed-citation></ref><ref id="ref-39"><label>39</label><mixed-citation publication-type="journal">
<article-title>COVID-19: Community News</article-title>. Oxford Nanopore Technologies. Accessed March 22, 2020.
<ext-link ext-link-type="uri" xlink:href="http://nanoporetech.com/about-us/news/covid19-community">Reference Source</ext-link>
</mixed-citation></ref><ref id="ref-40"><label>40</label><mixed-citation publication-type="journal">
<article-title>COVID-19 Map</article-title>. Johns Hopkins Coronavirus Resource Center. Accessed April 8, 2020.
<ext-link ext-link-type="uri" xlink:href="https://coronavirus.jhu.edu/map.html">Reference Source</ext-link>
</mixed-citation></ref><ref id="ref-41"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blalock</surname><given-names>G</given-names></name><name><surname>Kadiyali</surname><given-names>V</given-names></name><name><surname>Simon</surname><given-names>DH</given-names></name></person-group>:
<article-title>The Impact of Post-9/11 Airport Security Measures on the Demand for Air Travel</article-title>. 42.
<pub-id pub-id-type="doi">10.2139/ssrn.677563</pub-id>
</mixed-citation></ref></ref-list></back><sub-article id="report27443" article-type="peer-review"><front-stub><article-id pub-id-type="doi">10.21956/aasopenres.14154.r27443</article-id><title-group><article-title>Reviewer response for version 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mshana</surname><given-names>Stephen E.</given-names></name><xref ref-type="aff" rid="r27443a1">1</xref><role>Referee</role><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7526-6271</contrib-id></contrib><aff id="r27443a1">
<label>1</label>Microbiology and Immunology department, Weill Bugando School of Medicine, University of Health and Allied Sciences, Mwanza, Tanzania</aff></contrib-group><author-notes><fn fn-type="COI-statement"><p>
<bold>Competing interests: </bold>No competing interests were disclosed.</p></fn></author-notes><pub-date pub-type="epub"><day>26</day><month>5</month><year>2020</year></pub-date><permissions><copyright-statement>Copyright: &#x000a9; 2020 Mshana SE</copyright-statement><copyright-year>2020</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><related-article related-article-type="peer-reviewed-article" id="d36e2261" ext-link-type="doi" xlink:href="10.12688/aasopenres.13059.1">Version 1</related-article><custom-meta-group><custom-meta><meta-name>recommendation</meta-name><meta-value>approve</meta-value></custom-meta></custom-meta-group></front-stub><body><p>The letter is well written. It describes the current assays to detect COVID-19. It has clearly outlined the challenges and the need of point of care especially at this time of pandemics. The author needs to add information on sensitivity and specificity of assays for the reader to clearly understand the utility.</p><p>Does the article adequately reference differing views and opinions?</p><p>Yes</p><p>Are all factual statements correct, and are statements and arguments made adequately supported by citations?</p><p>Yes</p><p>Is the Open Letter written in accessible language?</p><p>Yes</p><p>Where applicable, are recommendations and next steps explained clearly for others to follow?</p><p>Yes</p><p>Is the rationale for the Open Letter provided in sufficient detail?</p><p>Yes</p><p>Reviewer Expertise:</p><p>Clinical Microbiology</p><p>I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.</p></body></sub-article><sub-article id="report27439" article-type="peer-review"><front-stub><article-id pub-id-type="doi">10.21956/aasopenres.14154.r27439</article-id><title-group><article-title>Reviewer response for version 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mukwaya</surname><given-names>Anthony</given-names></name><xref ref-type="aff" rid="r27439a1">1</xref><role>Referee</role><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9645-8942</contrib-id></contrib><aff id="r27439a1">
<label>1</label>Department of Ophthalmology, Institute for Clinical and Experimental Medicine, Faculty of Health Sciences,, Linkoping University, Link&#x000f6;ping, Sweden</aff></contrib-group><author-notes><fn fn-type="COI-statement"><p>
<bold>Competing interests: </bold>No competing interests were disclosed.</p></fn></author-notes><pub-date pub-type="epub"><day>6</day><month>5</month><year>2020</year></pub-date><permissions><copyright-statement>Copyright: &#x000a9; 2020 Mukwaya A</copyright-statement><copyright-year>2020</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><related-article related-article-type="peer-reviewed-article" id="d36e2345" ext-link-type="doi" xlink:href="10.12688/aasopenres.13059.1">Version 1</related-article><custom-meta-group><custom-meta><meta-name>recommendation</meta-name><meta-value>approve</meta-value></custom-meta></custom-meta-group></front-stub><body><p>The novel COVID-19 is thought to have originated from the city of Wuhan in China. This disease is now an ongoing global pandemic that has claimed thousands of lives, and with many more thousands diagnosed with the infection daily. Scientists around the world are working tirelessly to save lives by improving disease diagnosis, patient management strategies, means of containing disease spread, and working towards effective treatments. This calls for concerted action from the different governments, scientists, and the general population to combat this pandemic.</p><p> The review article by Mboowa Gerald titled: &#x02019;
<ext-link ext-link-type="uri" xlink:href="https://aasopenresearch.org/articles/3-8/v1">Current and emerging diagnostic tests available for the novel COVID-19 global pandemic</ext-link>&#x02019;, provides good background information on the infection and highlights the challenges faced by scientists, and suggests ways in which to overcome this pandemic. The author clearly and very nicely discusses the current, and emerging diagnostic tests for the novel COVID-19, including molecular and virological assays. The author describes point-of-care tests for disease diagnosis, highlighting; Xpert
<sup>&#x000ae;</sup> Xpress SARS-CoV-2 and Abbott ID COVID-19 tests, as an example of those that the US-FDA has granted emergency use authorization for diagnosis of the novel COVID-19. Furthermore, the author properly discusses whole-genome sequencing as an important component for disease management, by informing the design of appropriate molecular diagnostic tools, and for a better understanding of the pathophysiology of the disease.</p><p> Taken together, this review article by Mboowa Gerald is detailed, is up to date, and is a timely piece of document which embodies the concerted action required to overcome the current global pandemic.</p><p>
<bold>Minor comment for the author:</bold>
</p><p> In the description of the point-of-care tests for diagnosing COVID-19, the following sentence may be revised for clarity. &#x02018;It can amplify more than one genomic target and in the case of COVID-19 and these can be
<italic>ORF1ab</italic> of coronaviruses occupy about two thirds of their genomes&#x02019;.</p><p>Does the article adequately reference differing views and opinions?</p><p>Yes</p><p>Are all factual statements correct, and are statements and arguments made adequately supported by citations?</p><p>Yes</p><p>Is the Open Letter written in accessible language?</p><p>Yes</p><p>Where applicable, are recommendations and next steps explained clearly for others to follow?</p><p>Yes</p><p>Is the rationale for the Open Letter provided in sufficient detail?</p><p>Yes</p><p>Reviewer Expertise:</p><p>Transcriptomics, angiogenesis, molecular biology, diagnostics, infection, eye diseases</p><p>I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.</p></body></sub-article></article>